Item 8.01 Other Events

On November 30, 2022, Kintara Therapeutics, Inc. (the "Company") issued a press release announcing that on November 29, 2022, the Company received a letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company's shares of common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company's common stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

As described above, the following exhibits are furnished as part of this report:

Exhibit No. Description



99.1            Press Release issued by Kintara Therapeutics, Inc., dated November
              30, 2022

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses